Evotec, Halozyme and euro

Germany’s Evotec Gets Takeover Interest From Halozyme
Germany’s Evotec SE is attracting potential takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc., people familiar with the matter said.
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.
Evotec attracts takeover interest from Halozyme, Bloomberg says
EST Evotec (EVO) attracts takeover interest from Halozyme (HALO), Bloomberg says Published first on TheFly – the ultimate source
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley.
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at about 11 euros per share,
Evotec jumps as Halozyme confirms takeover interest (updated)
Evotec stock surges 10% as Halozyme Therapeutics expresses takeover interest, sparking investor excitement and speculation in the market.
FierceBiotech2d
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
BioPharma Dive2d
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer
Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...
Halozyme’s Strategic Acquisition of Evotec: A Buy Rating for Future Growth and Profitability
Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...
MarketWatch2d
Evotec Shares Surge on $2.11 Billion Buyout Offer
Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...
Evotec SE回应媒体猜测
德国汉堡 - 专注于药物发现和开发的制药公司Evotec SE今天向美国证券交易委员会提交了一份临时公告，回应了最近的媒体猜测。这家在法兰克福证券交易所以EVO为股票代码上市的公司，对有关其业务运营的报道作出了澄清。 在公告中，Evotec的首席执行官Christian Wojczewski表示："我们经常评估潜在的战略机会以提升股东价值，并将继续这样做。"Wojczewski强调，虽然公司愿意探 ...
JPMorgan thinks may take time for market to digest Halozyme bid for Evotec
After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR ...